BioCentury
ARTICLE | Politics, Policy & Law

Long-winded questions; short replies

October 14, 2002 7:00 AM UTC

Mark McClellan, the Bush administration's nominee to head the FDA, provided few real clues to what future agency policy might look like under his regime in written congressional testimony last week, although he did reveal some ambivalence about establishing a process for approving biologic generics and firm opposition to reimportation of pharmaceuticals from Canada.

McClellan provided terse responses to written questions posed by members of the Senate Health, Education, Labor and Pensions Committee. The answers - in most cases shorter than the lawmakers' queries - were calibrated to avoid political controversy and revealed little about McClellan's personal views...